Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas

被引：0
作者：
Pirazzoli, Valentina
Takezawa, Ken
de Stanchina, Elisa
Pao, William
Politi, Katerina
机构：
来源：
CLINICAL CANCER RESEARCH | 2012年 / 18卷 / 10期
关键词：
D O I：
10.1158/1078-0432.MECHRES-A38
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A38
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
    Akiko Takahashi
    Masahiro Seike
    Mika Chiba
    Satoshi Takahashi
    Shinji Nakamichi
    Masaru Matsumoto
    Susumu Takeuchi
    Yuji Minegishi
    Rintaro Noro
    Shinobu Kunugi
    Kaoru Kubota
    Akihiko Gemma
    Scientific Reports, 8
  • [22] Acquired Resistance to Afatinib in EGFR- Mutant Lung Cancer
    Sequist, L. V.
    Gerber, D. E.
    Fidias, P.
    Shaw, A. T.
    Temel, J. S.
    Heist, R. S.
    Gainor, J. F.
    Fulton, L.
    Kennedy, E. A.
    Muzikansky, A.
    Engelma, J. A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S43 - S44
  • [23] A Case of EGFR-mutant Squamous Cell Lung Cancer Treated With Necitumumab Combination Therapy
    Inomata, Minehiko
    Furukawa, Daisuke
    Takata, Naoki
    Tokui, Kotaro
    Okazawa, Seisuke
    Imanishi, Shingo
    Nomura, Satoshi
    IN VIVO, 2025, 39 (02): : 1207 - 1210
  • [24] Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer
    Takahashi, Akiko
    Seike, Masahiro
    Chiba, Mika
    Takahashi, Satoshi
    Nakamichi, Shinji
    Matsumoto, Masaru
    Takeuchi, Susumu
    Minegishi, Yuji
    Noro, Rintaro
    Kunugi, Shinobu
    Kubota, Kaoru
    Gemma, Akihiko
    SCIENTIFIC REPORTS, 2018, 8
  • [25] Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas
    Gow, Chien-Hung
    Chang, Hou-Tai
    Lim, Chor-Kuan
    Liu, Chao-Yu
    Chen, Jin-Shing
    Shih, Jin-Yuan
    GENES CHROMOSOMES & CANCER, 2017, 56 (05) : 373 - 381
  • [26] Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC
    Freydman, Jessica
    Henshaw, Lynnette
    Patel, Jasmine V.
    Smith, Claire E.
    Everett, Peter C.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (04) : 503 - 504
  • [27] Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization
    Bolan, Patrick O.
    Zviran, Asaf
    Brenan, Lisa
    Schiffman, Joshua S.
    Dusaj, Neville
    Goodale, Amy
    Piccioni, Federica
    Johannessen, Cory M.
    Landau, Dan A.
    CELL SYSTEMS, 2020, 10 (01) : 52 - +
  • [28] A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR-Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib
    Yu, Helena A.
    Perez, Leslie
    Chang, Qing
    Gao, Sizhi P.
    Kris, Mark G.
    Riely, Gregory J.
    Bromberg, Jacqueline
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : 102 - 109
  • [29] Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC).
    Marcoux, Nicolas
    Gettinger, Scott N.
    O'Kane, Grainne M.
    Arbour, Kathryn Cecilia
    Neal, Joel W.
    Husain, Hatim
    Evans, Tracey L.
    Brahmer, Julie R.
    Muzikansky, Alona
    Bonomi, Philip
    Del Prete, Salvatore A.
    Wurtz, Anna
    Farago, Anna F.
    Dias-Santagata, Dora
    Mino-Kenudson, Mari
    Yu, Helena Alexandra
    Wakelee, Heather A.
    Shepherd, Frances A.
    Piotrowska, Zofia
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
    Lee, Jiyun
    Piotrowska, Zofia
    Soo, Ross
    Cho, Byoung Chul
    Lim, Sun Min
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
12345